▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1221 by analyst upside · 2026-10-16
ARWR
Arrowhead Pharmaceuticals, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
+83.5%
implied upside to consensus target
Current Price $58.5
Consensus Target $107.36
Bull Target $126.0
Bear Target $74.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
9
Hold
1
Sell
0
52-Week Low $36.57
52-Week High $95.49
YTD Return -13.7%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.28
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $669M
Profit Margin -47.8%
52-WEEK RANGE
52-Week Low $36.57
52-Week High $95.49
Current Price $58.5
Bear Target $74.0
Bull Target $126.0
● Now $58.5 ● Target $107.36
TRADING DATA
Avg Volume 1.9M
YTD Return -13.7%
Analyst Count 14
Consensus Buy
Upside to Target +83.5%
Last Updated 2026-10-16

ANALYST SUMMARY

Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $58.5 with a Wall Street consensus price target of $107.36, implying potential upside of 83.5% over the next 12 months. 14 analysts currently cover ARWR, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $126.0, while the most cautious has a target of $74.0.

ARWR operates in the Healthcare sector with a market capitalisation of $8B. The stock is down 13.7% year-to-date and is currently trading near the lower end of its 52-week range of $36.57 – $95.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ARWR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup ● Initiated
Buy 2026-09-08 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-09-01 31% win rate (48 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-08-31 33% win rate (6 calls)
RBC Capital reit
Outperform → Outperform 2026-08-31 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-06 31% win rate (48 calls)
B. Riley Securities - Reiterated
Buy → Buy 2026-07-30 17% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-07-27 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-23 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
55
out of 100
Coverage depth
21/30
Consensus clarity
12/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →